Patents Examined by Jay F. Williams
-
Patent number: 5989552Abstract: Conjugates between one or more repeated subunits of an antigen and a carbohydrate polymer are desired. Also described are immunogenic vaccines against disease states which contain the conjugates and methods for inducing cell-mediated immune responses. The conjugates may especially contain polymers of the carbohydrate mannose and one or more repeated subunits of human mucin.Type: GrantFiled: April 9, 1997Date of Patent: November 23, 1999Assignee: Austin Research InstituteInventors: Ian F. C. McKenzie, Geoff Allen Pietersz, Vasso Apostolopoulos
-
Patent number: 5922328Abstract: A live, attenuated HSV-2 virus and methods of making and using the virus are provided. The live, attenuated HSV-2 virus is constructed using recombinant techniques and can be used in a pharmaceutical composition for prophylactic treatment of HSV-2 infections and for treatment of recurrent HSV-2 related diseases and conditions. Additionally, a plasmid vector is disclosed for expressing a GST-UL56 fusion protein wherein the protein comprises the Glutathione S Transferase gene product fused to at least an immunogenic portion of the HSV-2 UL56 gene product. The GST-UL56 fusion protein can be used to produce polyclonal antisera to the HSV-2 UL56 gene product, to detect whether recombinant HSV-2 deletion mutants express UL56, and as a type-specific reagent capable of discerning HSV-1 from HSV-2.Type: GrantFiled: September 6, 1996Date of Patent: July 13, 1999Assignee: AvironInventors: Frances C. Spector, Bernard Roizman, Richard Spaete
-
Patent number: 5917020Abstract: Crosslinking reagents for protein modification are provided, which comprise four functional, leaving groups capable of reacting with amino acid residues on the protein chains, one pair at each end of a relatively rigid chemical spacer group comprising aromatic residues joined by amide linkages. Such crosslinking reagents react with hemoglobin to effect intramolecular crosslinking of two dimeric hemoglobin units to stabilize the tetramers, by use of the respective pairs of functional groups, and to produce dimers of such tetrameric units, i.e. bis-tetrameric, intramolecularly crosslinked and stabilized hemoglobin, to the exclusion of higher molecular weight hemoglobin species.Type: GrantFiled: January 15, 1997Date of Patent: June 29, 1999Inventors: Ronald H. Kluger, Jodi J.L. Lock-O'Brien
-
Patent number: 5889168Abstract: A nucleic acid comprising a sequence encoding a fusion protein comprising a portion of the glycoprotein B of HCMV fused to a portion of the glycoprotein D of HSV-2.Type: GrantFiled: November 18, 1996Date of Patent: March 30, 1999Assignee: SmithKline Beecham s.a.Inventor: Dirk Richard Gheysen
-
Patent number: 5872206Abstract: The invention provides for compositions and methods for interfering with Hepatitis B viral infection that are based on the interaction of Hepatitis B virus X protein with a novel proteasome subunit.Type: GrantFiled: October 6, 1994Date of Patent: February 16, 1999Assignee: The General Hospital CorporationInventors: Tsanyang Jake Liang, Jiakang Huang
-
Patent number: 5858442Abstract: A protein crumble having fat-like properties is made by using a soy protein which is mixed with water and then chopped and blended. Specific amounts of isolate soy protein or soy protein concentrate are preferred. Any of a number of ingredients including animal derived proteins, carbohydrates, and gums may be added to produce a fat-like attribute without actually adding fat.Type: GrantFiled: February 5, 1997Date of Patent: January 12, 1999Assignee: Archer Daniels Midland CompanyInventors: Tony Payne, Russ Egbert
-
Patent number: 5837312Abstract: A method for debittering and reducing the allergenic reactivity of protein hydrolysates is disclosed, which method includes the providing of an aqueous solution of a protein hydrolysate, feeding the solution into a bed of siloxane, and collecting a first portion of the solution exiting from the bed. The first portion contains either a non-bitter or bitter fraction. A second portion of the solution exiting from the bed can be collected which contains the opposite tasting fraction of the hydrolysate. Preferably the siloxane is selected from the group comprising octa-siloxane and octadecyl-siloxane. Preferably the hydrolysate has a molecular weight of less than 10,000, and is derived from the group of hydrolysates comprising casein, whey and soy. Additionally, the bed preferably is of a depth of between 2 to 4 times the bed diameter. A more hypoallergenic protein hydrolysate product produced in accordance with the method of the invention is also disclosed.Type: GrantFiled: September 20, 1996Date of Patent: November 17, 1998Assignee: Abbott LaboratoriesInventors: Christopher T. Cordle, Shih-Bin Lin, Lynn P. Nelles, Ronald L. Thomas
-
Patent number: 5804551Abstract: A method for improving recovery after surgery or an invasive procedure is provided, including administering a hemoglobin preparation to a patient before surgery or an invasive procedure.Type: GrantFiled: November 12, 1996Date of Patent: September 8, 1998Assignee: Baxter International Inc.Inventor: Kenneth E. Burhop
-
Patent number: 5795710Abstract: A method for culturing an organic tissue comprising: attaching the tissue onto an inner side of a mesh which is placed in an incubation chamber, and culturing the tissue in the presence of a culture medium and a gas containing oxygen under a condition that the ratio of the contact time of the tissue with the culture medium to that with the gas lies in a range from 1:2.5 to 1:3.5.Type: GrantFiled: January 27, 1997Date of Patent: August 18, 1998Inventor: Sung-Su Park
-
Patent number: 5770689Abstract: An antigen composition hepatitis E virus (HEV) infection are disclosed. The antigen composition includes peptides corresponding to carboxyl terminal end regions of the second and third open reading frames of the HEV genome.Type: GrantFiled: June 7, 1995Date of Patent: June 23, 1998Assignees: Genelabs Technologies, Inc., The United States of America as represented by the Department of Health and Human ServicesInventors: Gregory R. Reyes, Daniel W. Bradley, Jr-Shin Twu, Michael A. Purdy, Albert W. Tam, Krzysztof Z. Krawczynski, Patrice O. Yarbough
-
Patent number: 5760185Abstract: An anti-FHV-1 recombinant antibody efficacious for treatment, prevention and diagnosis of feline herpes virus-1 (FHV-1) and a gene fragment useful for preparing the same are provided. A cell producing a mouse monoclonal antibody having an excellent neutralizing activity against FHV-1 was constructed, and a gene fragment coding for V region of said antibody responsible for the specific binding activity against FHV-1 was obtained. Using this gene fragment and a gene fragment coding for the constant region of a feline antibody, a chimeric anti-FHV-1 recombinant antibody is obtained.Type: GrantFiled: May 26, 1995Date of Patent: June 2, 1998Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteInventors: Kazuhiko Kimachi, Hiroaki Maeda, Kiyoto Nishiyama, Sachio Tokiyoshi
-
Patent number: 5750350Abstract: The entire genome of the hepatitis D virus has been shown to be a circular single-stranded RNA Of 1679 bases. Several open reading frames in both the genomic and complementary strands indicate possible protein products. The products encoded in one open reading frame, ORF5, are identified as viral polypeptides p24.sup..delta. and p27.sup..delta. of which the nuclear .delta. antigens in HDV infected liver is comprised. These products, as well as others encoded in ORFs 1, 2, 6, and 7 are produced in recombinant expression systems. The ORF5 products, in particular, are useful for HDV diagnosis and vaccines.Type: GrantFiled: May 24, 1995Date of Patent: May 12, 1998Assignee: Chiron CorporationInventors: Michael Houghton, Kang-Sheng Wang, Qui-Lim Choo, Amy Joan Weiner, Lacy Rasco Overby
-
Patent number: 5739292Abstract: A fusion protein comprising a portion of a glycoprotein of HCMV fused to a portion of a glycoprotein of HSV is described.Type: GrantFiled: May 18, 1995Date of Patent: April 14, 1998Assignee: SmithKline Beecham Biologicals (s.a.)Inventor: Dirk Richard Gheysen
-
Patent number: 5670312Abstract: Antibodies are recovered and isolated from the sera of a number "n" of patients each of which have or have had the same given disease so that each of the "n" patients has, within a large number of different antibodies, some antibodies uniquely associated with the same disease of interest. The antibodies of a first patient are bound to a support surface. To carry out initial screening libraries of molecules are brought into contact with the bound antibodies of the first patient under conditions where binding will occur. Secondary screening is then carried out by extracting and labeling the antibodies of a second patient and using the labeled antibodies to probe the molecules (peptides) isolated in the initial screening. Many of the non-disease specific antibodies (of the second patient) will not bind to the molecules (peptides) of the isolated bacteriophage which bound to the antibodies of the first patient.Type: GrantFiled: November 17, 1995Date of Patent: September 23, 1997Inventor: Daniel V. Santi